Trubion Pharmaceuticals Announces Presentation Of Positive Data From Phase IIb And Re-treatment Studies With TRU-015 In Patients With Arthritis

Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) announced presentation of positive data from a Phase IIb study that showed that Trubion’s TRU-015 for rheumatoid arthritis (RA) provided statistically significant efficacy after a single infusion of 800 mg or 1,600 mg. In addition, Trubion also announced presentation of data showing that repeat administration with TRU-015 was well tolerated and resulted in a consistent pharmacokinetic (PK) and pharmacodynamic (PD) profile. [click link for full article]

More: continued here

Filed under: Arthritis on November 9th, 2007